Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

• DOI: 10.2147/ceor.s167727
• Publication Date: 2018-11-11T19:58:01Z
• Authors: Erin Johansson; Mercedes Nuñez; Axel Svedbom; Tatiana Dilla; Susanne Hartz
• Keywords: Ixekizumab; Maintenance therapy; Ustekinumab

Currently, several biologic agents are available for the treatment of moderate-to-severe plaque psoriasis, including newer with similar mechanisms action and efficacy; therefore, there is a need to evaluate their efficiency in terms cost effectiveness.This study evaluates effectiveness recently approved interleukin (IL)-17A antagonists, ixekizumab secukinumab, psoriasis from perspective Spanish National Health System (NHS).A Markov model lifetime horizon was developed compare vs. secukinumab hypothetical cohort patients psoriasis. The used monthly cycles included four health states: 12-week induction period, maintenance, best supportive care (BSC), death. Patients meeting response criteria at end period transitioned maintenance therapy, whereas non-responders BSC. It assumed that, each year, 20% receiving therapy would discontinue treatment. incorporated data various sources, published literature, network meta-analysis, expert opinion some variables.Ixekizumab dominant over that it gained 0.037 more quality-adjusted life years (QALYs) saved €1951 total costs horizon. Probabilistic sensitivity analysis showed 96.6% likelihood be effective threshold €30,000 per QALY gained.For Spain, provided additional QALYs potential savings NHS compared secukinumab. Since magnitude differences modest, other factors such as patient preferences (eg, number injections) long-term safety related time on market) may also important guiding clinical decisions.